MKMatthew P. Kosloski

Matthew P. Kosloski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Matthew P. Kosloski has a total of 192 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacokinetics, efficacy and safety of dupilumab administered with prefilled pen devices in patients aged <12 years with atopic dermatitis

    by Amy S. Paller, Elaine C. Siegfried, Ashish Bansal, Jing Xiao, Faisal A. Khokhar, Michael Van Spall, Xia Liu, Christine Xu, Ariane Dubost‐Brama, Matthew P. Kosloski

    Aim: For children with atopic dermatitis (AD), dupilumab is available as a prefilled syringe (PFS) from the age of 6 months and as a prefilled pen (PFP) for patients aged ≥2 years, in 200‐ and 300‐mg devices. This substudy of an ongoing open‐label extension study evaluated the pharmacokinetics, efficacy and safety of switching from a dupilumab PFS device to a PFP device in children aged 2–11 years with AD. Methods: Patients received 200 mg of dupilumab every 2 weeks (q2w, Cohort 1B) or 300 mg of dupilumab every 4 weeks (q4w, Cohorts 1A and 2B) based on age (2–5 or 6–11 years) and weight (15–C max ; 4 days post‐dose) and steady‐state trough concentration ( C trough ; 14 or 28 days post‐dose for q2w or q4w), collected after the PFS (reference) and the last PFP (test) doses. Results: Geometric mean ratios (PFP/PFS) of C max were 1.019, 0.834 and 0.807 for Cohorts 1A, 1B and 2B, respectively, and 0.896, 1.152 and 0.817 for C trough , respectively, indicating a similar drug exposure between PFS and PFP in each cohort. No patients exhibited treatment‐emergent antidrug antibody responses after switching to PFP, and dupilumab was well tolerated. Conclusion: These results support the use of dupilumab via 200‐mg and 300‐mg PFP devices for patients aged 2–11 years with AD. Clinical trial registration number: ClinicalTrials.gov Identifier: NCT02612454, posted on 23 November 2015.

  • Open Access

    Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis

    by Matthew P. Kosloski, Ching-Ha Lai, Michael A. Partridge, Vanaja Kanamaluru, Ashish Bansal, Brad Shumel, Marius Ardeleanu, Hong Yan, Christine Xu, Ainara Rodríguez Marco, et al.

    Of the original article "Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis." Dupilumab is a monoclonal antibody used to treat atopic dermatitis (AD) in patients 6 months and older. Antibody drugs can induce immunogenicity by activating patient's immune system to produce antidrug antibodies (ADAs). Some ADAs may impact drug's activity ("neutralizing antibodies" [NAbs]) and/or safety. In this study, we evaluated anti-dupilumab ADAs in patients with AD from seven randomized controlled trials (N = 2992) and two open-label extensions (OLEs; N = 2287). The highest proportion of patients with ADAs in any study was 9%, 16%, 5%, and 2% in adults, adolescents, children, and infants, respectively. In any trial, fewer than 1% of patients had high-titer ADAs and up to 5% had NAbs. With longer observation in OLEs, most high or moderate ADA titers decreased over time while patients continued dupilumab treatment. Except in some rare cases of high-titer ADAs, the pharmacokinetics, efficacy, and safety of dupilumab were similar between ADA-positive and ADA-negative patients. One patient with high-titer ADAs developed serum sickness and discontinued dupilumab. In conclusion, most dupilumab-treated patients across age groups did not develop ADAs. Most ADA-positive patients had low-titer, NAb-negative ADAs. Most ADA-positive patients benefited from continuing dupilumab treatment [1] (Fig. 1).

  • Open Access

    Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis

    by Jenny‐Hoa Nguyen, Mirna Chehade, Evan S. Dellon, Allen Radin, Jason Chittenden, Mohamed A. Kamal, Margee Louisias, Christine Xu, Matthew P. Kosloski

    Dupilumab, a fully human monoclonal antibody that blocks key drivers of type 2 inflammation, is approved across 8 diseases, including eosinophilic esophagitis. Subcutaneous dupilumab 300 mg weekly improved outcomes vs. placebo in adults (aged ≥ 18 years) and adolescents (aged ≥ 12 to < 18 years) during the phase III LIBERTY EoE TREET study (NCT03633617). The phase III EoE KIDS study (NCT04394351) demonstrated efficacy of a weight‐tiered, higher exposure dupilumab dose approximating 300 mg weekly exposure in TREET vs. placebo in children aged ≥ 1 to < 12 years. To characterize dupilumab pharmacokinetics, inform clinical trial design, and optimize posology, a population pharmacokinetic model was developed using dupilumab concentration data from 6 single‐dose studies in healthy adults and 3 eosinophilic esophagitis clinical trials. Healthy volunteer data were used to construct a stable base model; incorporation of patient data allowed estimation covariate effects for the disease population. Observational data from up to 52 weeks of treatment in eosinophilic esophagitis trials validated model performance. Significant effects were identified for body weight on clearance and volume of distribution, including time‐varying weight in children and adolescents, and of albumin on clearance; age was not a significant covariate. Simulations identified alternative dupilumab regimens for patients weighing ≥ 5 to <15 kg (200 mg every 3 weeks) and ≥ 40 to <60 kg (300 mg weekly) with improved exposure matching to the 300 mg weekly dose in TREET. The final model was used to inform regulatory approval and potential future clinical trial design.

  • Top Cited Papers
    Open Access

    Dupilumab: Mechanism of action, clinical, and translational science

    by Marc R. McCann, Matthew P. Kosloski, Christine Xu, John D. Davis, Mohamed A. Kamal

    Allergic disease prevalence has increased globally with the subset of type 2 inflammatory diseases playing a substantial role. Type 2 inflammatory diseases may differ in clinical presentation, but they exhibit shared pathophysiology that is targeted by the unique pharmacology of dupilumab. Dupilumab binds to the interleukin (IL)‐4 receptor alpha subunit (IL‐4Rα) that blocks IL‐4 and IL‐13 signaling, two key drivers of type 2 inflammation. Herein, we review the mechanism of action and pharmacology of dupilumab, and the clinical evidence that led to the regulatory approvals of dupilumab for the treatment of numerous type 2 inflammatory diseases: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis.


  • Open Access

    Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials

    by Matthew P. Kosloski, Emma Guttman‐Yassky, Michael J. Cork, Margitta Worm, Dong‐Ho Nahm, Xiaoping Zhu, Marcella K. Ruddy, Sivan Harel, Mohamed A. Kamal, Hélène Goulaouic, et al.

    Interleukin‐33 (IL‐33) is a proinflammatory alarmin cytokine released by damaged epithelial tissue cells that initiates and amplifies both type 1 and type 2 inflammatory cascades. A role for IL‐33 in atopic dermatitis (AD; a chronic, relapsing type 2 inflammatory disease of the skin) has been proposed. Itepekimab is a novel human IgG4P monoclonal antibody against IL‐33, currently in clinical development for chronic obstructive pulmonary disease (COPD). Two global phase II studies—a dose‐ranging itepekimab monotherapy study (NCT03738423) and a proof‐of‐concept study of itepekimab alone and in combination with dupilumab (NCT03736967)—were conducted in patients with moderate‐to‐severe AD to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy; both studies were terminated following an interim analysis of the proof‐of‐concept study, which failed to demonstrate the efficacy of itepekimab. In these two studies, itepekimab exhibited linear and dose‐proportional pharmacokinetics. Pharmacodynamics of total IL‐33 indicated that itepekimab saturated binding to the target in serum at 300 mg q2w and q4w doses, and decreased blood eosinophil counts. Concentration–time profiles of itepekimab and total IL‐33 were similar for itepekimab with or without dupilumab, and between East Asian and non‐East Asian subgroups. Itepekimab was generally well tolerated, both alone and in combination with dupilumab. The lack of clinical efficacy for itepekimab observed in these studies suggests that IL‐33 may not be a key pathogenic driver in moderate‐to‐severe AD.


  • Top Cited Papers
    Open Access

    Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development

    by John D. Davis, Marçal Bravo Padros, Daniela J. Conrado, Samit Ganguly, Xiaowen Guan, Hazem E. Hassan, Anasuya Hazra, Susan C. Irvin, Priya Jayachandran, Matthew P. Kosloski, et al.

    Subcutaneous (s.c.) administration of monoclonal antibodies (mAbs) can reduce treatment burden for patients and healthcare systems compared with intravenous (i.v.) infusion through shorter administration times, made possible by convenient, patient‐centric devices. A deeper understanding of clinical pharmacology principles related to efficacy and safety of s.c.‐administered mAbs over the past decade has streamlined s.c. product development. This review presents learnings from key constituents of the s.c. mAb development pathway, including pharmacology, administration variables, immunogenicity, and delivery devices. Restricted mAb transportation through the hypodermis explains their incomplete absorption at a relatively slow rate (pharmacokinetic (PK)) and may impact mAb‐cellular interactions and/or onset and magnitude of physiological responses (pharmacodynamic). Injection volumes, formulation, rate and site of injection, and needle attributes may affect PKs and the occurrence/severity of adverse events like injection‐site reactions or pain, with important consequences for treatment adherence. A review of immunogenicity data for numerous compounds reveals that incidence of anti‐drug antibodies (ADAs) is generally comparable across i.v. and s.c. routes, and complementary factors including response magnitude (ADA titer), persistence over time, and neutralizing antibody presence are needed to assess clinical impact. Finally, four case studies showcase how s.c. biologics have been clinically developed: (i) by implementation of i.v./s.c. bridging strategies to streamline PD‐1/PD‐L1 inhibitor development, (ii) through co‐development with i.v. presentations for anti‐severe acute respiratory syndrome‐coronavirus 2 antibodies to support rapid deployment of both formulations, (iii) as the lead route for bispecific T cell engagers (BTCEs) to mitigate BTCE‐mediated cytokine release syndrome, and (iv) for pediatric patients in the case of dupilumab.


  • Open Access

    Characterizing complex and competing drug–drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine

    by Matthew P. Kosloski, Hong Li, Stanley Wang, Federico Mensa, Jens Kort, Wei Liu

    The fixed‐dose combination of the direct acting antivirals glecaprevir (GLE) and pibrentasvir (PIB) is an oral, once‐daily treatment for all six major genotypes of chronic hepatitis C virus infection. A single and multiple‐dose rifampin study (N = 12) and a carbamazepine study (N = 12) were conducted in healthy subjects to evaluate the effects of CYP3A/P‐gp induction and OATP inhibition on the pharmacokinetics of GLE and PIB. In study 1, GLE 300 mg + PIB 120 mg was administered as a single dose either alone, after single and multiple daily doses of rifampin 600 mg, or 24 h after the last rifampin dose. In study 2, GLE 300 mg + PIB 120 mg was administered as a single dose either alone or after multiple doses of carbamazepine 200 mg. Relative to GLE + PIB alone, exposure of GLE was significantly increased by the first co‐administered rifampin dose due to OATP inhibition, significantly decreased 24 h after the last rifampin dose due to CYP3A/P‐gp induction, and slightly increased when co‐administered with steady‐state rifampin due to a combination of inhibition and induction forces. Exposure of PIB was not affected when co‐administered with the first rifampin dose but was significantly decreased with steady‐state rifampin co‐administration, or 24 h after the last rifampin dose due to P‐gp induction. Carbamazepine significantly decreased GLE and PIB exposure, mainly attributed to P‐gp induction. The regimens tested were generally well‐tolerated by the subjects and no new safety issues were identified.


  • Open Access

    Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first‐in‐human and first‐in‐patient trials

    by Matthew P. Kosloski, George D. Kalliolias, Christine R. Xu, Sivan Harel, Ching‐Ha Lai, Wenjun Zheng, John D. Davis, Mohamed A. Kamal

    Itepekimab is a monoclonal antibody that targets interleukin (IL‐33) and has been shown to reduce airway inflammation and associated tissue damage in preclinical studies. We assessed the safety, tolerability, pharmacokinetics (PKs), and pharmacodynamic profiles of single‐ascending and multiple‐ascending doses of itepekimab in two randomized, double‐blind, placebo‐controlled phase I studies. Healthy adults (N = 40) were randomized to the single‐dose study and patients with moderate asthma (N = 23) to the multiple‐dose study. Itepekimab was administered intravenously (0.3, 1, 3, or 10 mg/kg infusion) or subcutaneously (150 mg) in the single‐dose study and subcutaneously (75 or 150 mg weekly for 4 weeks) in the multiple‐dose study. Itepekimab exhibited linear PKs across studies and dose‐proportional increases in mean maximum concentration in serum and area under the concentration–time curve following single intravenous or multiple subcutaneous doses. Itepekimab demonstrated mean subcutaneous bioavailability of 59–73% and a long terminal half‐life (30.0–31.6 days). IL‐33 concentrations in most healthy participants and patients with asthma were undetectable at baseline. Following administration of itepekimab in both studies, total IL‐33 concentrations increased and blood eosinophils decreased, both with durable effect. Itepekimab was well‐tolerated in both studies with no detection of treatment‐emergent anti‐drug antibody responses.


  • Open Access

    Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer

    by Jonathan W. Goldman, Minal Barve, Jyoti D. Patel, Antoinette Wozniak, Afshin Dowlati, Alexander Starodub, Taofeek K. Owonikoko, William Edenfield, Scott A. Laurie, Daniel Da Costa, et al.

    Small cell lung cancer (SCLC) is a leading cause of cancer death worldwide, with few treatment options. Rovalpituzumab tesirine (Rova‐T) is an antibody‐drug conjugate that targets delta‐like 3 on SCLC cells to deliver a cytotoxic payload directly to tumor cells. In this study, the cardiac safety profile of Rova‐T was assessed by evaluating changes in QT interval, electrocardiogram (ECG) waveform, heart rate, and proarrhythmic adverse events (AEs) after treatment with Rova‐T in patients with previously treated extensive‐stage SCLC. Patients underwent ECG monitoring for 2 weeks after each of 2 i.v. infusions of 0.3 mg/kg Rova‐T over 30 minutes, administered 6 weeks apart. Forty‐six patients received at least one dose of Rova‐T. At the geometric mean Rova‐T maximum serum concentration of 7,940 ng/mL, ECG monitoring showed no significant changes in the Fridericia‐corrected QT (QTcF) interval; the upper limit of the 2‐sided 90% confidence interval did not exceed 10 msec for any time point. There were no clinically significant changes in QRS or PR intervals, ECG waveforms, or heart rate after Rova‐T administration. All patients experienced a treatment‐emergent AE (TEAE); 78% had a grade ≥ 3 TEAE, 59% had a serious TEAE, and 41% had a cardiac‐related TEAE. The TEAEs that might signal proarrhythmia tendencies were uncommon. Confirmed partial responses were observed in 24% of patients. Based on the evaluation of ECG data collected in this study from patients treated with Rova‐T at 0.3 mg/kg i.v. administered every 6 weeks, a QTcF effect of clinical concern can be excluded.


  • Open Access

    Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir

    by Matthew P. Kosloski, Daniel A.J. Bow, Ryota Kikuchi, Haoyu Wang, Elaine J. Kim, Kennan Marsh, Federico Mensa, Jens Kort, Wei Liu

    Glecaprevir and pibrentasvir are oral direct-acting antiviral agents approved in combination for treatment of chronic hepatitis C viral infection. In vitro studies identified the combination as potential clinically relevant inhibitors of the efflux transporters P glycoprotein (P-gp), breast cancer resistance protein (BCRP), and hepatic uptake transporters organic anion transporting polypeptide (OATP) 1B1/3. Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 µM, respectively. Pibrentasvir inhibited P-gp, BCRP, and OATP1B1 with IC50 values of 0.036, 14, and 1.3 µM, respectively. Neither agent inhibited organic cation transporter (OCT) 1, OCT2, organic anion transporter (OAT) 1, OAT3, multidrug and toxin extrusion (MATE) 1, or MATE2K. Open-label Phase 1 clinical drug-drug interaction studies were conducted in healthy subjects to evaluate interaction potential of glecaprevir/pibrentasvir and coadministered selective substrates for P-gp (digoxin, dabigatran etexilate, sofosbuvir), BCRP (rosuvastatin, sofosbuvir), and OATP1B1/3 (pravastatin, rosuvastatin). Pharmacokinetic parameters maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) were evaluated for probe substrates alone and in combination with glecaprevir/pibrentasvir. Cmax central values increased by 72%, 105%, 123%, 462%, and 66% for digoxin, dabigatran, pravastatin, rosuvastatin, and sofosbuvir, respectively. AUC central values increased by 48%, 138%, 130%, 115%, and 125% for digoxin, dabigatran, pravastatin, rosuvastatin, and sofosbuvir, respectively. Exposure of sofosbuvir metabolite GS-331007 was similar with or without glecaprevir/pibrentasvir. Outcomes of the clinical drug-drug interaction studies confirmed clinically relevant inhibition of P-gp, BCRP, and OATP1B1/3, and were used to provide dosing guidance for the concomitant use of glecaprevir/pibrentasvir with relevant transporter substrates. SIGNIFICANCE STATEMENT N/A